Fatty acid synthase: a new anti-tumor target;Sintasa de ácidos grasos como nueva diana antitumoral

Medicina Clinica

Volumn 132, Issue 9, 2009, Pages 359-363

  Puig, Teresa ^a,b   Porta, Rut ^a   Colomer, Ramon ^a,c  

^a GIRONA BIOMEDICAL RESEARCH INSTITUTE IDIBGI   (Spain)

^b UNIVERSITY OF GIRONA   (Spain)

^c MD ANDERSON CANCER CENTER   (Spain)

Author keywords

Cancer; Fatty acid metabolism; Fatty acid synthase; New antitumor drugs

Indexed keywords

ANTINEOPLASTIC AGENT; C 75; CERULETIDE; EPICATECHIN; EPICATECHIN GALLATE; EPIGALLOCATECHIN; EPIGALLOCATECHIN GALLATE; FATTY ACID SYNTHASE; FATTY ACID SYNTHASE INHIBITOR; TETRAHYDROLIPSTATIN; TRICLOSAN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CELL; CANCER THERAPY; CARCINOGENESIS; CYTOTOXICITY; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; FATTY ACID METABOLISM; HUMAN; LIVER CANCER; LUNG CANCER; NONHUMAN; PROGNOSIS; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; SKIN CANCER; TEA;

ANTINEOPLASTIC AGENTS; FATTY ACID SYNTHETASE COMPLEX; HUMANS; NEOPLASMS; PROGNOSIS;

EID: 62149091043     PISSN: 00257753     EISSN: 15788989     Source Type: Journal    
DOI: 10.1016/j.medcli.2008.07.022     Document Type: Review

References (48)

1. Milgraum L.Z., Witters L.A., Pasternack G.R., and Kuhajda F.P. Enzymes of the fatty acid synthesis pathway are highly expressed in situ breast carcinoma. Clin Cancer Res 3 (1997) 2115-2120
2. Epstein J.I., Carmichael M., and Partin A.W. OA-519 (fatty acid synthase) as an independent predictor of pathologic state in adenocarcinoma of the prostate. Urology 45 (1995) 81-86
3. Swinnen J.V., Roskams T., Joniau S., Van Poppel H., Oyen R., Baert L., et al. Overexpression of fatty acid synthase is an early and common event in the development of prostate cancer. Int J Cancer 98 (2002) 19-22
4. Visca P., Sebastiani V., Botti C., Diodoro M.G., Lassagni R.P., Romagnoli F., et al. Fatty acid synthase (FAS) is a marker of increased risk of recurrence in lung carcinoma. Anticancer Res 24 (2004) 4169-4173
5. Zhao W., Kridel S., Thorbum A., Kooshki M., Little J., Hebbar S., et al. Fatty acid synthase: a novel target for antiglioma therapy. Br J Cancer 95 (2006) 869-878
6. Kuhajda F.P. Fatty acid synthase and cancer: new application of an old pathway. Cancer Res 66 (2006) 5977-5980
7. Maier T., Jenni S., and Ban N. Architecture of mammalian fatty acid synthase at 4.5 Å resolution. Science 311 (2006) 1258-1262
8. Barlett K., and Eaton S. Mitochondrial beta-oxidation. Eur J Biochem 271 (2004) 462-469
9. Pizer E.S., Jackisch C., Wood F.D., Pasternack G.R., Davidson N.E., Kuhajda F.P., et al. Inhibition of fatty acid synthesis induces programmed cell death in human breast cancer cells. Cancer Res 56 (1996) 2745-2747
10. Kuhajda F.P., Pizer E.S., Li J.N., Mani N.S., Frehywot G.L., Townsend C.A., et al. Synthesis and antitumor activity of an inhibitor of fatty acid synthase. Proc Natl Acad Sci U S A 97 (2000) 3450-3454
11. Gabrielson E.W., Pinn M.L., Testa J.R., and Kuhajda F.P. Increased fatty acid synthase is a therapeutic target in mesothelioma. Clin Cancer Res 7 (2001) 153-157
12. Menendez J.A., Lupu R., and Colomer R. Targeting fatty acid synthase: potential for therapeutic intervention in HER-2/neu-overexpressing breast cancer. Drug News Perspect 18 (2005) 375-385
13. Chalbos D., Chambon M., Ailhaud G., and Rochefort H. Fatty acid synthetase and its mRNA are induced by progestins in breast cancer cells. J Biol Chem 262 (1987) 9923-9926
14. Swinnen J.V., Esquenet M., Goossens K., Heyns W., and Verhoeven G. Androgens stimulate fatty acid synthase in the human prostate cancer cell line LNCaP. Cancer Res 57 (1997) 1086-1090
15. Ettinger S.L., Sobel R., Whitmore T.G., Akbari M., Bradley D.R., Gleave M.E., et al. Dysregulation of sterol response element-binding proteins and downstream effectors in prostate cancer during progression to androgen independence. Cancer Res 64 (2004) 2212-2221
16. Pizer E.S., Pflug B.R., Bova G.S., Han W.F., Udan M.S., and Nelson J.B. Increased fatty acid synthase as a therapeutic target in androgen-independent prostate cancer progression. Prostate 47 (2001) 102-110
17. Wang Y., Kuhajda F.P., Sokoll L.J., and Chan D.W. Two-site ELISA for the quantitative determination of fatty acid synthase. Clin Chim Acta 304 (2001) 107-115
18. Fukuda H., Iritani N., Sugimoto T., and Ikeda H. Transcriptional regulation of fatty acid synthase gene by insulin/glucose, polyunsaturated fatty acid and leptin in hepatocytes and adipocytes in normal and genetically obese rats. Eur J Biochem 260 (1999) 505-511
19. Yang Y.A., Han W.F., Morin P.J., Chrest F.J., and Pizer E.S. Activation of fatty acid synthesis during neoplastic transformation: role of mitogen-activated protein kinase and phosphatidylinositol 3-kinase. Exp Cell Res 279 (2002) 80-90
20. Menendez J.A., Vellon L., Mehmi I., Oza B.P., Ropero S., Colomer R., et al. Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells. Proc Natl Acad Sci U S A 101 (2004) 10715-10720
21. Yoon S., Lee M.Y., Park S.W., Moon J.S., Koh Y.K., Ahn Y.H., et al. Up-regulation of acetyl-CoA carboxylase alpha and fatty acid synthase by human epidermal growth factor receptor 2 at the translational level in breast cancer cells. J Biol Chem 282 (2007) 26122-26131
22. Menendez J.A., Mehmi I., Verma V.A., Teng P.K., and Lupu R. Pharmacological inhibition of fatty acid synthase (FAS): a novel therapeutic approach for breast cancer chemoprevention through its ability to suppress Her-2/neu (erbB-2) oncogene-induced malignant transformation. Mol Carcinog 41 (2004) 164-178
23. Bandyopadhyay, Pai S.K., Watabe M., Gross S.C., Hirota S., Hosobe S., et al. FAS expression inversely correlates with PTEN level in prostate cancer and a PI 3-kinase inhibitor synergizes with FAS siRNA to induce apoptosis. Oncogene 24 (2005) 5389-5395
24. Van de Sande T., Roskams T., Lerut E., Joniau S., Van Poppel H., Verhoeven G., et al. High-level expression of fatty acid synthase in human prostate cancer tissues is linked to activation and nuclear localization of Akt/PKB. J Pathol 206 (2005) 214-219
25. Wang Y., Kuhajda F.P., Li J.N., Pizer E.S., Han W.F., Sokoll L.J., et al. Fatty acid synthase (FAS) expression in human breast cancer cell culture supernatants and in breast cancer patients. Cancer Lett 167 (2001) 99-104
26. Zhang D., Tai L.K., Wong L.L., Chiu L.L., Sethi S.K., Koay E.S., et al. Proteomic study reveals that proteins involved in metabolic and detoxification pathways are highly expressed in HER-2/neu-positive breast cancer. Mol Cell Proteomics 4 (2005) 1686-1696
27. Wang Y., Zhang X.R., Fu J., Tan W., and Zhang. [Prognostic value of expression of FASE, HER-2/neu, bcl-2 and p53 in stage I non-small cell lung cancer]. Zhonghua Zhong Liu Za Zhi 26 (2004) 369-372
28. Sebastiani V., Visca P., Botti C., Santeusanio G., Galati G.M., Piccini V., et al. Fatty acid synthase is a marker of increased risk of recurrence in endometrial carcinoma. Gynecol Oncol 92 (2004) 101-105
29. Kapur P., Rakheja D., Roy L.C., and Hoang M.P. Fatty acid synthase expression in cutaneous melanocytic neoplasms. Mod Pathol 18 (2005) 1107-1112
30. Innocenzi D., Alo P.L., Balzani A., Sebastiani V., Silipo V., La Torre G., et al. Fatty acid synthase expression in melanoma. J Cutan Pathol 30 (2003) 23-28
31. Takahiro T., Shinichi K., and Toshimitsu S. Expression of fatty acid synthase as a prognostic indicator in soft tissue sarcomas. Clin Cancer Res 9 (2003) 2204-2212
32. Wang Y.Y., Kuhajda F.P., Li J., Finch T.T., Cheng P., Koh C., et al. Fatty acid synthase as a tumor marker: its extracellular expression in human breast cancer. J Exp Ther Oncol 4 (2004) 101-110
33. Alo P.L., Visca P., Trombetta G., Mangoni A., Lenti L., Monaco S., et al. Fatty acid synthase (FAS) predictive strength in poorly differentiated early breast carcinomas. Tumori 85 (1999) 35-40
34. Omura S. The antibiotic cerulenin, a novel tool for biochemistry as an inhibitor of fatty acid synthesis. Bacteriol Rev 40 (1976) 681-697
35. Alli P.M., Pinn M.L., Jaffee E.M., McFadden J.M., and Kuhajda F.P. Fatty acid synthase inhibitors are chemopreventive for mammary cancer in neu-N transgenic mice. Oncogene 24 (2005) 39-46
36. Wang H.Q., Altomare D.A., Skele K.L., Poulikakos P.I., Kuhajda F.P., Di Cristofano A., et al. Positive feedback regulation between AKT activation and fatty acid synthase expression in ovarian carcinoma cells. Oncogene 24 (2005) 3574-3582
37. Loftus T.M., Jaworsky D.E., Frehywot G.L., Townsend C.A., Ronnett G.V., Lane M.D., et al. Reduced food intake and body weight in mice treated with fatty acid synthase inhibitors. Science 288 (2000) 2379-2381
38. Aja S., Landree L.E., Kleman A.M., Medghalchi S.M., Vadlamudi A., Mc Fadden J.M., et al. Pharmacological stimulation of brain carnitine palmitoyl-transferase-1 decreases food intake and body weight. Am J Physiol Regul Integr Comp Physiol 294 (2008) R352-R361
39. Puig T, Relat J, Porta R, Casals G, Marrero PF, Haro D, et al. (-)-Epigallocatechin-3-gallate inhibits fatty acid synthase in breast cancer cells and does not induce weight loss in vivo. The European Cancer Conference (ECCO14). Barcelona, 23-27 septiembre 2007.
40. Jatoi A., Ellison N., Burch P.A., Sloan J.A., Dakhil S.R., Novotny P., et al. A phase II trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma. Cancer 97 (2003) 1442-1446
41. Choan E., Segal R., Jonker D., Malone S., Reaume N., Eapen L., et al. A prospective clinical trial of green tea for hormone refractory prostate cancer: an evaluation of the complementary/alternative therapy approach. Urol Oncol 23 (2005) 108-113
42. Puig T., Vazquez-Martin A., Relat J., Petriz J., Menendez J.A., Porta R., et al. Fatty acid metabolism in breast cancer cells: differential inhibitory effects of epigallocatechin gallate (EGCG) and C75. Breast Cancer Res Treat 109 (2007) 471-479
43. Vergote D., Cren-Olive C., Chopin V., Toillon R.A., Rolando C., Hondermarck H., et al. (-)-Epigallocatechin (EGC) of green tea induces apoptosis of human breast cancer cells but not of their normal counterparts. Breast Cancer Res Treat 76 (2002) 195-201
44. Yeh C.W., Chen W.J., Chiang C.T., Lin-Shiau S.Y., and Lin J.K. Suppression of fatty acid synthase in MCF-7 breast cancer cells by tea and tea polyphenols: a possible mechanism for their hypolipidemic effects. Pharmacogenomics J3 (2003) 267-276
45. Brusselmans K., De Schrijver E., Heyns W., Verhoeven G., and Swinnen J.V. Epigallocatechin-3-gallate is a potent natural inhibitor of fatty acid synthase in intact cells and selectively induces apoptosis in prostate cancer cells. Int J Cancer 106 (2003) 856-862
46. Brusselmans K., De Schrijver E., Verhoeven G., and Swinnen J.V. RNA interference-mediated silencing of the acetyl-CoA-carboxylase-alpha gene induces growth inhibition and apoptosis of prostate cancer cells. Cancer Res 65 (2005) 6719-6725
47. Colomer R, Puig T, Brunet J, Turrado C, Ortega-Gutiérrez S, Benhamú B, et al. Novel polyhydroxylated compounds as fatty acid synthase (FASN). Patent EP07110956. 2007.
48. Puig T., Benhamú B., Turrado C., Relat J., Ortega-Gutiérrez S., Marrero P.F., et al. Novel polyphenolic inhibitors of fatty acid synthase (FASN) have potential as anticancer agents. American Association for Cancer Research (AACR) (2008) 11-18 Abril. San Diego, EEUU